Antigen persistence of rapid diagnostic tests in pregnant women in Nanoro, Burkina Faso, and the implications for the diagnosis of malaria in pregnancy

Tropical Medicine & International Health, 04/16/2012

Histidine–rich protein 2 (HRP2) can persist up to 28 days after artemisinin–based combination therapy (ACT) treatment; therefore, this test is not suitable for treatment follow–up in pregnant women and can generate problems when using this test during intermittent preventive treatment (IPTp). Dihydrofolate reductase–thymidylate synthase is less persistent than HRP2, making it a potentially interesting target for diagnosis.

Print Article Summary Cat 2 CME Report